Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616641 | 0.83 | APP (0.50) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6027644 | 0.77 | CYP1A2 (0.63) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3920520 | 0.75 | GAA (0.54) | LMNAAPPTP53GAAMAPT | |
| SCHEMBL11578826 | 0.74 | APP (0.79) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5633306 | 0.74 | APP (0.79) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL10399449 | 0.73 | MAOB (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL21699890 | 0.73 | MAOB (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3618116 | 0.73 | APP (0.69) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL11601389 | 0.73 | APP (0.69) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3629799 | 0.73 | MAOB (0.56) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | LMNA 1505/4885CYP1A2 642/4885PTGS1 1562/4885 |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | LMNA 1698/4885CYP1A2 265/4885PTGS1 1139/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | LMNA 1331/4885CYP1A2 583/4885PTGS1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.